vs
Side-by-side financial comparison of FREQUENCY ELECTRONICS INC (FEIM) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $17.1M, roughly 1.6× FREQUENCY ELECTRONICS INC). FREQUENCY ELECTRONICS INC runs the higher net margin — 10.5% vs -5.9%, a 16.4% gap on every dollar of revenue. On growth, FREQUENCY ELECTRONICS INC posted the faster year-over-year revenue change (8.3% vs 4.6%). Sanara MedTech Inc. produced more free cash flow last quarter ($3.9M vs $-1.1M). Over the past eight quarters, Sanara MedTech Inc.'s revenue compounded faster (21.8% CAGR vs 11.8%).
Ultra Electronics Holdings is a British defence and security company. It was listed on the London Stock Exchange and was a constituent of the FTSE 250 Index until it was acquired by Cobham, which is itself owned by Advent International.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
FEIM vs SMTI — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.1M | $27.5M |
| Net Profit | $1.8M | $-1.6M |
| Gross Margin | 38.2% | 93.2% |
| Operating Margin | 10.0% | 23.5% |
| Net Margin | 10.5% | -5.9% |
| Revenue YoY | 8.3% | 4.6% |
| Net Profit YoY | -32.1% | 5.3% |
| EPS (diluted) | $0.18 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.1M | $27.5M | ||
| Q3 25 | $13.8M | $26.3M | ||
| Q2 25 | $20.0M | $25.8M | ||
| Q1 25 | $18.9M | $23.4M | ||
| Q4 24 | $15.8M | $26.3M | ||
| Q3 24 | $15.1M | $21.7M | ||
| Q2 24 | $15.6M | $20.2M | ||
| Q1 24 | $13.7M | $18.5M |
| Q4 25 | $1.8M | $-1.6M | ||
| Q3 25 | $634.0K | $-30.4M | ||
| Q2 25 | $3.2M | $-2.0M | ||
| Q1 25 | $15.4M | $-3.5M | ||
| Q4 24 | $2.7M | $-1.7M | ||
| Q3 24 | $2.4M | $-2.9M | ||
| Q2 24 | $2.6M | $-3.5M | ||
| Q1 24 | $130.0K | $-1.8M |
| Q4 25 | 38.2% | 93.2% | ||
| Q3 25 | 36.8% | 92.9% | ||
| Q2 25 | 37.5% | 92.5% | ||
| Q1 25 | 43.8% | 92.2% | ||
| Q4 24 | 48.2% | 91.4% | ||
| Q3 24 | 44.4% | 90.8% | ||
| Q2 24 | 40.3% | 90.0% | ||
| Q1 24 | 22.6% | 89.8% |
| Q4 25 | 10.0% | 23.5% | ||
| Q3 25 | 2.6% | 11.2% | ||
| Q2 25 | 16.4% | -0.1% | ||
| Q1 25 | 18.3% | -8.9% | ||
| Q4 24 | 16.5% | 18.6% | ||
| Q3 24 | 15.7% | 3.6% | ||
| Q2 24 | 16.0% | -14.3% | ||
| Q1 24 | -3.4% | -8.3% |
| Q4 25 | 10.5% | -5.9% | ||
| Q3 25 | 4.6% | -115.5% | ||
| Q2 25 | 16.0% | -7.8% | ||
| Q1 25 | 81.4% | -15.1% | ||
| Q4 24 | 16.8% | -6.5% | ||
| Q3 24 | 16.1% | -13.2% | ||
| Q2 24 | 16.9% | -17.4% | ||
| Q1 24 | 0.9% | -9.5% |
| Q4 25 | $0.18 | $-0.32 | ||
| Q3 25 | $0.07 | $-3.40 | ||
| Q2 25 | $0.33 | $-0.23 | ||
| Q1 25 | $1.60 | $-0.41 | ||
| Q4 24 | $0.28 | $-0.18 | ||
| Q3 24 | $0.25 | $-0.34 | ||
| Q2 24 | $0.28 | $-0.41 | ||
| Q1 24 | $0.01 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $58.5M | $5.9M |
| Total Assets | $92.3M | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $16.6M | ||
| Q3 25 | $4.5M | $14.9M | ||
| Q2 25 | $4.7M | $17.0M | ||
| Q1 25 | $5.5M | $20.7M | ||
| Q4 24 | $9.7M | $15.9M | ||
| Q3 24 | $16.2M | $16.3M | ||
| Q2 24 | $18.3M | $6.2M | ||
| Q1 24 | $11.7M | $2.8M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $58.5M | $5.9M | ||
| Q3 25 | $56.3M | $6.1M | ||
| Q2 25 | $55.6M | $35.4M | ||
| Q1 25 | $51.8M | $36.7M | ||
| Q4 24 | $36.2M | $39.4M | ||
| Q3 24 | $33.2M | $39.8M | ||
| Q2 24 | $39.8M | $41.7M | ||
| Q1 24 | $36.7M | $43.3M |
| Q4 25 | $92.3M | $72.9M | ||
| Q3 25 | $93.2M | $71.1M | ||
| Q2 25 | $93.7M | $98.8M | ||
| Q1 25 | $86.4M | $96.4M | ||
| Q4 24 | $77.8M | $88.1M | ||
| Q3 24 | $84.3M | $88.5M | ||
| Q2 24 | $83.3M | $73.4M | ||
| Q1 24 | $77.7M | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-523.0K | $3.9M |
| Free Cash FlowOCF − Capex | $-1.1M | $3.9M |
| FCF MarginFCF / Revenue | -6.6% | 14.0% |
| Capex IntensityCapex / Revenue | 3.6% | 0.3% |
| Cash ConversionOCF / Net Profit | -0.29× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-5.5M | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-523.0K | $3.9M | ||
| Q3 25 | $1.2M | $2.2M | ||
| Q2 25 | $-155.0K | $2.7M | ||
| Q1 25 | $-3.6M | $-2.0M | ||
| Q4 24 | $3.8M | $932.0K | ||
| Q3 24 | $-1.5M | $2.1M | ||
| Q2 24 | $7.5M | $-1.4M | ||
| Q1 24 | $4.2M | $-1.6M |
| Q4 25 | $-1.1M | $3.9M | ||
| Q3 25 | $385.0K | $1.1M | ||
| Q2 25 | $-786.0K | $902.7K | ||
| Q1 25 | $-4.0M | $-3.7M | ||
| Q4 24 | $3.3M | $859.9K | ||
| Q3 24 | $-1.8M | $2.0M | ||
| Q2 24 | $6.7M | $-1.5M | ||
| Q1 24 | $3.9M | $-1.7M |
| Q4 25 | -6.6% | 14.0% | ||
| Q3 25 | 2.8% | 4.2% | ||
| Q2 25 | -3.9% | 3.5% | ||
| Q1 25 | -20.9% | -15.9% | ||
| Q4 24 | 20.8% | 3.3% | ||
| Q3 24 | -11.8% | 9.4% | ||
| Q2 24 | 42.8% | -7.3% | ||
| Q1 24 | 28.4% | -9.0% |
| Q4 25 | 3.6% | 0.3% | ||
| Q3 25 | 5.6% | 4.0% | ||
| Q2 25 | 3.2% | 6.8% | ||
| Q1 25 | 1.7% | 7.4% | ||
| Q4 24 | 3.3% | 0.3% | ||
| Q3 24 | 2.2% | 0.0% | ||
| Q2 24 | 5.3% | 0.3% | ||
| Q1 24 | 2.3% | 0.4% |
| Q4 25 | -0.29× | — | ||
| Q3 25 | 1.83× | — | ||
| Q2 25 | -0.05× | — | ||
| Q1 25 | -0.24× | — | ||
| Q4 24 | 1.44× | — | ||
| Q3 24 | -0.60× | — | ||
| Q2 24 | 2.85× | — | ||
| Q1 24 | 32.36× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FEIM
| POC Revenue | $14.8M | 86% |
| POT Revenue | $2.3M | 13% |
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
